Cardiac glycosides inhibit LPS-induced activation of pro-inflammatory cytokines in whole blood through an NF-κB-dependent mechanism

International Journal of Applied Research in Natural Products

Volumn 4, Issue 1, 2011, Pages 11-19

  Shah, V O ^a   Ferguson, J ^a   Hunsaker, L A ^a   Deck, L M ^b   Jagt, Vander ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cardiovascular disease; End stage renal disease; Inflammation; Natural products; NF B

Indexed keywords

BACTERIA (MICROORGANISMS); STROPHANTHUS GRATUS;

EID: 80051919205     PISSN: None     EISSN: 19406223     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Aggarwal BB, Shishodia S. 2004. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for the seasoning. Ann NY Acad Sci 1030: 434-441.
2. Bachovchin DA, Brown SJ, Rosen H, Cravatt BF. 2009. Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat Biotechnol 27(4):387-394.
3. Bremner P, Heinrich M. 2002. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54(4):453-472.
4. Bommer J, Becker KP, Urbaschek R. 1996. Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol 7(6):883-888.
5. Boon-Unge K, Yu Q, Zou T, Zhou A, Govitrapong P, Zhou J. 2007. Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem Biol 14(12):1386-1392.
6. Canaud B, Cristol JP, Morena M, Leray-Moragues H, Bose JY, Vaussenat F. 1999. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 17(2-3):99-106.
7. Descamps-Latscha B, Drueke T, Witko-Sarsat V. 2001. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 14(3):193-199.
8. DeWardener HE, Clarkson EM. 1985. Concept of natriuretic hormone. Physiol Rev 65(3):658-759.
9. Nicholls MG, Lewis LK, Yandle TG, Lord G, McKinnon W, Hilton PJ. 2009. Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease. Fact or fantasy? J Hypertens 27(1):3-8.
10. Fedorova OV, Shapiro JI, Bagrov AY. 2010. Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim Biophys Acta 1802(12):1230-1236.
11. Felth J, Rickardson L, Rosen J, Wickstrom M, Fryknas M, Lindskog M, et al. 2009. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. J Nat Prod 72(11):1969-1974.
12. Filiopoulos V, Vlassopoulos D. 2009. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 8(5):369-382.
13. French HA. 2009. Nutrition and muscle catabolism in maintenance hemodialysis: does feeding make muscle cells selective self-eaters? J Ren Nutr 19(1):86-90.
14. Gilmore TD, Herscovitch M. 2006. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25(51):6887-6899.
15. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, et al. 2001. Elevated plasma F2- isoprostanes in patients on long-term hemodialysis. Kidney Int 59(5):1960-1966.
16. Himmelfarb J, Lazaus JM, Hakim RM. 1991. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during hemodialysis. Am J Kidney Dis 17(3):271-276.
17. Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134(5):703-707.
18. Ihenetu K, Espinosa R, de Leon R, Planas G, Perez-Pinero A, Waldbeser L. 2008. Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. Inflamm Res 57(11):519-523.
19. Islam Z, Gray JS, Pestka JJ. 2006. p38 Mitogen-activated protein kinase mediates IL-8 induction by the ribotoxin deoxynivalenol in human monocytes. Toxicol Appl Pharmacol 213(3):235-244.
20. Jagielska J, Salguero G, Schieffer B, Bavendiek U. 2009. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis? Atherosclerosis 206(2):390-396.
21. Karin M, Yamamoto Y, Wang QM. 2004. The IKK NF-κB system: a treasure trove for drug development. Nature Rev Drug Discov 3(1):17-26.
22. Larsson DE, Hassan S, Larsson R, Oberg K, Granberg D. 2009. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines. Cancer Chemother Pharmacol 65(1):5-12.
23. Laude-Sharp M, Caroff M, Simard L, Pusineri C, Kazatchkine MD, Haeffner-Cavaillon N. 1990. Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int 38(6):1089-1094.
24. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. 2010. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107(5):2037-2042.
25. Li J, Zelenin S, Aperia A, Aizman O. 2006. Low doses of ouabain protect from serum deprivation-triggered apoptosis and stimulate kidney cell proliferation via activation of NF-kappaB. J Am Soc Nephrol 17(7):1848-1857.
26. Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. 2003. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18(7):1272-1280.
27. Lopez-Lazaro M. 2007. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11(8):1043-1053.
28. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, et al. 1997. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 96(5):1501-1506.
29. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. 2000. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 12(3):294-297.
30. McIntyre CW, Odudu A, Eldehni MT. 2009. Cardiac assessment in chronic kidney disease. Curr Opin Nephrol Hypertens 18(6):501-506.
31. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, et al. 2001. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60(5):1844-1850.
32. Miller SC, Huang R, Sakamura S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. 2010. Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem Pharmacol 79(9):1272-1280.
33. Nagase S, Aoyagi K, Hirayama A, Gotoh M, Ueda A, Tomida C, et al. 1997. Favorable effect of hemodialysis on decreased serum antioxidant activity in hemodialysis patients demonstrated by electron spin resonance. J Am Soc Nephrol 8(7):1157-1163.
34. Nam NH. 2006. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6(8):945-951.
35. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV. 2009. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8(23):3960-3970.
36. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, et al. 2001. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16(2):335-340.
37. Panichi V, Migliori M, De Pietro S, Taccola D, Andreini B, Metelli MR, et al. 2000. The link of biocompatibility to cytokine production. Kidney Int Suppl 76:S96-103.
38. Pertosa G, Marfella C, Tarantino EA, Di Cillo M, Manno C, Russo R, et al. 1991. Involvement of peripheral blood monocytes in haemodialysis: in vivo induction of tumour necrosis factor alpha, interleukin 6 and beta 2- microglobulin. Nephrol Dial Transplant 6(Suppl 2):18-23.
39. Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP. 1993. C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int Suppl 41:S221-S225.
40. Raff AC, Meyer TW, Hostetter TH. 2008. New Insights into uremic toxicity. Curr Opin Nephrol Hypertens 17(6):560-565.
41. Raj DS, Boivin MA, Dominic EA, Boyd A, Roy PK, Rihani T, et al. 2007. Hemodialysis induces mitochondrial dysfunction and apoptosis. Eur J Clin Invest 37(12):971-977.
42. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR. 1995. Detection of oxidants in uremic plasma by electron spin resonance spectroscope. Kidney Int 48(1):199-206.
43. Sela S, Shurtz-Swirski R, Shapiro G, Nasser L, Hamzi M, Shasha SM, et al. 2001. Oxidative stress during hemodialysis: Effect of heparin. Kidney Int Suppl 78:S159-S163.
44. Shah VO, Ferguson JE, Hunsaker LA, Deck LM, Vander Jagt DL. 2010. Natural products inhibit LPS-induced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Nat Prod Res 24(12):1177-1188.
45. Shimizu M, Weinstein IB. 2005. Modulation of signal transduction by tea catechins and related phytochemicals. Mutat Res 591(1-2):147-160.
46. Sies H. 1997. Oxidants and antioxidants. Exp Physiol 82(2):291-195.
47. +-dependent amino acid transport. Biochem Pharmacol 78(9):1157-1166.
48. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49(5):1304-1313.
49. Xiao C, Ghosh S. 2005. NF-kB, an evolutionary conserved mediator of immune and inflammatory responses. Adv Exp Med Biol 560:41-45.
50. Yamazaki S, Takeshige K. 2008. Protein synthesis inhibitors enhance the expression of mRNAs for early inducible inflammatory genes via mRNA stabilization. Biochim Biophys Acta 1779(2):108-114.